Burning Mouth Syndrome Clinical Trial
Official title:
Comparative Evaluation of Vortioxetine Versus Other Antidepressants With Pregabalin Augmentation in Treatment-resistant Burning Mouth Syndrome: a Prospective Longitudinal Clinical Trial With Treatment Response Prediction
Background: The treatment of Burning Mouth Syndrome (BMS) presents a challenge in tailoring appropriate medication for individual patients. Antidepressants have demonstrated efficacy in alleviating symptoms in most cases; however, a subset of patients exhibit limited or no response to these treatments. The augmentation with pregabalin to conventional treatment has shown promising outcomes in relieving pain and improving quality of life in chronic pain conditions. This study aimed to compare the efficacy of vortioxetine with other antidepressants (SSRIs/SNRIs) in combination with pregabalin in a cohort of unresponsive BMS patients and to predict treatment response using clinical data. Methods: A 52-week randomized, open-label, active-controlled study was conducted, enrolling 203 BMS patients previously treated with one antidepressant for 12 weeks and non-responder to the treatment. The study sample have included two groups: Group A (136) received vortioxetine, while Group B (67) received SSRIs/SNRIs. Pregabalin (75mg/day) was added to both groups, with a potential dosage increase to 150mg/day for inadequate responders after 12 weeks. Treatment response was assessed by measuring reduction in VAS and SF-MPQ scores (>50 or 1-2) and HAM-A and HAM-D scores (>50% or ≤7) at 12, 24, 36 and 52 weeks. Classical logistic regression with a stepwise algorithm and Random Forest machine learning models were used to predict treatment response.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04475614 -
Therapeutic Options for Treatment of Burning Mouth Syndrome
|
N/A | |
| Completed |
NCT00374673 -
Efficacy of Transcranial Magnetic Stimulation (TMS) in Chronic Idiopathic Pain Disorders
|
Phase 3 | |
| Completed |
NCT02964728 -
Botulinum Toxin in Burning Mouth Syndrome
|
Phase 2 | |
| Completed |
NCT04535973 -
Hormonal Status and Quality of Life in Female Postmenopausal Patients With Burning Mouth Syndrome
|
||
| Recruiting |
NCT06040190 -
Effect of Treatments on Pain and Quality of Life in Individual With Burning Mouth Syndrome
|
Phase 4 | |
| Not yet recruiting |
NCT05059418 -
Burning Mouth Syndrome - New Diagnostic Criteria and Treatment
|
N/A | |
| Recruiting |
NCT01867151 -
Effect of Gluten Free Diet in Patients With Burning Mouth Syndrome
|
N/A | |
| Completed |
NCT05872789 -
Impact of Diazepam 1% Oral Gel Efficacy in Burning Mouth Syndrome
|
N/A | |
| Completed |
NCT05871580 -
Effect to the Photobiomodulation in the Burning Mouth Syndrome
|
N/A | |
| Recruiting |
NCT05309070 -
The Efficacy of N-acetyl-cysteine in the Treatment of Burning Mouth Syndrome
|
N/A | |
| Completed |
NCT05399238 -
Thermography and Burning Mouth Syndrome
|
||
| Completed |
NCT02580734 -
Efficacy of Melatonin in Burning Mouth Syndrome (BMS)
|
N/A | |
| Completed |
NCT02382029 -
Acupuncture Versus Clonazepam in Burning Mouth Syndrome
|
Phase 0 | |
| Recruiting |
NCT05819697 -
Reducing Patient Memory Recall in the Burning Mouth Patient Population
|
||
| Completed |
NCT02757612 -
Study Evaluating the Laser Diode Effect Burning Mouth Syndrome
|
N/A | |
| Completed |
NCT00862576 -
A Study of the Association of Sleep Dysfunction and Burning Mouth Syndrome
|
N/A | |
| Not yet recruiting |
NCT04189367 -
Treatment of Burning Mouth Syndrome With Integration of Traditional Chinese Medicine and Western Medicine
|
Phase 3 | |
| Completed |
NCT00001524 -
Thalidomide to Treat Oral Lesions in HIV-Infected Patients
|
Phase 2 | |
| Recruiting |
NCT04481841 -
Head Yuanshi Dian Therapy in Burning Mouth Syndrome
|
Early Phase 1 | |
| Completed |
NCT02686359 -
Opiorphin Levels in Fluids of Burning Mouth Syndrome Patients (OPIODYN)
|
N/A |